Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: An updated analysis of a randomized trial

Breast Cancer Research and Treatment

Volumn 58, Issue 2, 1999, Pages 151-156

  Broët, Philippe ^a,b   Scholl, Susan M ^a   De la Rochefordière, Anne ^a   Fourquet, Alain ^a   Moreau, Thierry ^b   De Rycke, Yann ^a   Asselain, Bernard ^a   Pouillart, Pierre ^a  

^a INSTITUT CURIE   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Breast cancer; Long term effect; Primary chemotherapy; Short term effect; Weighted logrank tests

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MORTALITY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0033428140     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006339918798     Document Type: Article

References (24)

1. 1. Fisher B: Adjuvant therapy on node-negative breast cancer. J Clin Oncol 13: 537-540, 1995
2. 2. Bonadonna G, Valagussa P, Zucali R, Salvadori B: Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 45: 227-243, 1995
3. 3. Harris L, Swain S: The role of primary chemotherapy in early breast cancer. Semin Oncol 23: 31-42, 1996
4. 4. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangié T, Jouve M, Beuzeboc P, Garcio-Giralt E, Salmon RJ, De la Rochefordière A, Campana F, Pouillart P: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered as too large for breast conserving surgery: Preliminary results of a randomised trial, S6. Eur J Cancer 30A: 645-652, 1994
5. 5. Scholl SM, Asselain B, Beuzeboc P, Pierga JY, Dorval T, Garcia-Giralt E, Jouve M, Palangié T, Fourquet A, Durand JC, Pouillart P: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for conserving surgery: An update. Anti-Cancer Drugs 6: 69, (abstract P48) 1995
6. 6. Harris JR, Hellman S: Observations on survival curve analysis with particular reference to breast cancer treatment. Cancer 57: 925-928, 1986
7. 7. Peto R, Peto J: Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc Series A 135: 185-206, 1972
8. 8. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. Springer, New York, 1997
9. 9. Gregory WM, Bolland K, Whitehead J, Souhami RL: Cautionary tales of survival analysis: conflicting analyses from a clinical trial in breast cancer. Br J Cancer 76 (4): 551-558, 1997
10. 10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
11. 11. Nelson W: Hazard plotting for incomplete failure data. J Qual Techn 1: 27-52, 1969
12. 12. Gray R, Tsiatis A: A linear rank test for use when the main interest is in differences in cure rates. Biometrics 45: 899-904, 1989
13. 13. Moreau T, Maccario J, Lellouch J, Huber C: Weighted log rank statistics for comparing two distributions. Biometrika 79: 195-198, 1992
14. 14. Grambsch P, Therneau T: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526, 1994
15. 15. Mauriac L, Durand M, Avril A, Dilhuydy JM: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3 cm. Ann Oncol 2: 347-354, 1991
16. 16. Semiglazov VF. Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova O, Seleznev IK, Orlov AA, Barash NY, Golubeva OM, Chepic OF: Primary neoadjuvant chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIa breast cancer. Ann Oncol 2: 591-595, 1994
17. 17. Fisher B, Bryant J, Wolmark N, Manounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov N, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998
18. 18. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124 months median follow-up. Ann Oncol 10: 47-52, 1999
19. 19. Gamel JW, Vogel RL, McLean IW: Assessing the impact of adjuvant therapy on cure rate for stage 2 breast carcinoma. Br J Cancer 68: 115-118, 1993
20. 20. Gamel JW, Vogel RL, Valagussa P, Bonadonna G: Parametric survival analysis of adjuvant therapy for stage II breast cancer. Cancer 74: 2483-2490, 1994
21. 21. Maller R, Zhou X: Survival Analysis with Long-Term Survivors. Wiley, New York, 1996
22. 22. Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488-1492, 1983
23. 23. Lindley C, Vasa S, Sawyer WT, Winer EP: Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 16: 1380-1387, 1998
24. 24. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S: Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up. J Clin Oncol 16: 1144-1151, 1995